Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
| Status: | Suspended |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/13/2018 |
| Start Date: | August 2014 |
| End Date: | July 2019 |
Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response
to treatment in patients with advanced kidney cancer. Comparing results of diagnostic
procedures done before, during, and after targeted therapy may help doctors predict a
patient's response to treatment and help plan the best treatment.
to treatment in patients with advanced kidney cancer. Comparing results of diagnostic
procedures done before, during, and after targeted therapy may help doctors predict a
patient's response to treatment and help plan the best treatment.
Inclusion Criteria:
- Suspected or biopsy-proven renal cell carcinoma
- Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib,
nivolumab alone or in combination with an investigational agent
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Serum creatinine greater than or equal to 1.7 mg/dL
- Severe allergy to contrast agent
- Any contraindication for undergoing a CT scan
- Pregnancy or unwillingness to use preventative measures if a woman of child-bearing
potential
We found this trial at
1
site
Stanford University Cancer Institute The Stanford Cancer Institute (SCI) focuses the world-class expertise of more...
Click here to add this to my saved trials
